
Shares of drug developer Anebulo Pharmaceuticals ANEB.O rise 16.9% to $2.35 in early morning trading
Anebulo Pharmaceuticals says it is still considering a plan to go private after it first announced it in July 2025, but has also received interest from possible buyers and partners
The company's board will review different options to maximize shareholder value, including the going-private deal with a reverse stock split, a potential sale of its assets, or a merger, the company says
As of last close, ANEB was down 19.6% YTD